GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (FRA:NNFN) » Definitions » PensionAndRetirementBenefit

MannKind (FRA:NNFN) PensionAndRetirementBenefit : €0.0 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is MannKind PensionAndRetirementBenefit?

MannKind's PensionAndRetirementBenefit for the quarter that ended in Mar. 2024 was €0.0 Mil.


MannKind PensionAndRetirementBenefit Historical Data

The historical data trend for MannKind's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind PensionAndRetirementBenefit Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MannKind Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MannKind PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


MannKind (FRA:NNFN) Business Description

Industry
Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind (FRA:NNFN) Headlines

No Headlines